Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Website: vervetx.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -4.6% (LTM)

Entry Point: Share price is 274.7% higher than minimum and 73.2% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: VERV
Share price, USD:  (0.0%)11.13
year average price 6.29  


year start price 7.40 2024-07-27

min close price 2.97 2025-04-08

max close price 11.38 2025-06-17

current price 11.13 2025-07-26
Common stocks: 17 739 487

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 197
Net Debt ($m): -90
EV (Enterprise Value): 107
Price to Book: 0.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-06-17zacks.com

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

2025-06-17schaeffersresearch.com

Biotech Stock Surging on Billion-Dollar Buyout

2025-06-17prnewswire.com

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

2025-05-14zacks.com

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

2025-04-18fool.com

Why Verve Therapeutics Zoomed 40% Higher This Week

2025-04-15zacks.com

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

2025-01-31prnewswire.com

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

2025-01-23zacks.com

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

2025-01-19accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation

2024-12-13accesswire.com

VERV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VERV VERV VERV VERV VERV VERV VERV VERV VERV
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-05 2024-08-08 2024-05-08 2024-02-27 2023-11-07 2023-08-10 2023-05-15 2023-03-02 2022-11-07
acceptedDate 2024-11-05 07:30:23 2024-08-08 07:30:24 2024-05-08 07:30:33 2024-02-27 08:00:41 2023-11-07 07:30:31 2023-08-10 07:30:56 2023-05-15 07:33:51 2023-03-02 07:31:06 2022-11-07 07:33:07
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 7M 7M 6M 5M 3M 2M 1M 1M 929 000
costOfRevenue 2M 2M 2M 2M 3M 3M 0 0 0
grossProfit 5M 5M 4M 4M -82 000 -933 000 1M 1M 929 000
grossProfitRatio 0.745 0.751 0.713 0.705 -0.026 -0.446 1 1 1
researchAndDevelopmentExpenses 50M 51M 48M 47M 44M 47M 47M 37M 35M
generalAndAdministrativeExpenses 14M 15M 14M 12M 12M 13M 13M 11M 10M
sellingAndMarketingExpenses 0 -2M -2M -2M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 14M 13M 13M 11M 12M 13M 13M 11M 10M
otherExpenses 0 2M 78 000 -713 000 802 000 -662 000 738 000 2M 0
operatingExpenses 64M 64M 61M 58M 55M 61M 60M 49M 45M
costAndExpenses 64M 66M 63M 59M 55M 61M 60M 49M 45M
interestIncome 7M 7M 8M -17M 6M 5M 6M -2M 2M
interestExpense 0 0 0 6M 0 0 -6M -7M 2M
depreciationAndAmortization 2M 2M 2M 2M 1M 1M 1M 925 000 0
ebitda -55M -57M -55M -52M -52M -57M -58M -47M -44M
ebitdaratio -8.034 -8.543 -9.695 -10.193 -16.79 -27.351 -41.495 -46.23 -47.212
operatingIncome -57M -59M -57M -54M -52M -59M -58M -48M -44M
operatingIncomeRatio -8.29 -8.792 -9.981 -10.488 -16.79 -27.99 -41.495 -47.144 -47.212
totalOtherIncomeExpensesNet 7M 9M 8M 6M 7M -662 000 6M 7M -1M
incomeBeforeTax -50M -50M -49M -48M -46M -54M -52M -41M -45M
incomeBeforeTaxRatio -7.288 -7.433 -8.539 -9.393 -14.659 -25.708 -37.019 -40.545 -48.644
incomeTaxExpense 104 000 66 000 106 000 32 000 -67 000 176 000 -6M 53 000 1M
netIncome -50M -50M -49M -48M -46M -54M -46M -41M -47M
netIncomeRatio -7.303 -7.442 -8.558 -9.4 -14.68 -25.792 -32.543 -40.598 -50.075
eps -0.6 -0.59 -0.59 -0.69 -0.72 -0.87 -0.74 -0.67 -0.81
epsdiluted -0.59 -0.59 -0.59 -0.69 -0.72 -0.87 -0.74 -0.67 -0.81
weightedAverageShsOut 84M 84M 83M 70M 63M 62M 62M 61M 57M
weightedAverageShsOutDil 85M 84M 83M 70M 63M 62M 62M 61M 57M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VERV VERV VERV VERV VERV VERV VERV VERV VERV
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-05 2024-08-08 2024-05-08 2024-02-27 2023-11-07 2023-08-10 2023-05-15 2023-03-02 2022-11-07
acceptedDate 2024-11-05 07:30:23 2024-08-08 07:30:24 2024-05-08 07:30:33 2024-02-27 08:00:41 2023-11-07 07:30:31 2023-08-10 07:30:56 2023-05-15 07:33:51 2023-03-02 07:31:06 2022-11-07 07:33:07
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 159M 141M 144M 206M 78M 70M 509M 115M 551M
shortTermInvestments 381M 434M 462M 418M 407M 392M 425M 439M 274M
cashAndShortTermInvestments 540M 576M 606M 624M 485M 462M 509M 555M 551M
netReceivables 3M 3M 6M 6M 3M 2M 1M 1M 929 000
inventory 0 0 0 1 0 1 -9M 0 0
otherCurrentAssets 14M 12M 8M 8M 10M 8M 8M 7M 10M
totalCurrentAssets 556M 591M 620M 638M 498M 473M 509M 563M 562M
propertyPlantEquipmentNet 100M 102M 105M 108M 108M 110M 111M 111M 106M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 5M 5M 5M 5M 5M 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 8M 3M 3M 2M 2M 1M 15M 5M 5M
totalNonCurrentAssets 107M 110M 112M 115M 114M 116M 126M 116M 112M
otherAssets 0 0 1 0 0 0 0 0 0
totalAssets 664M 701M 732M 753M 612M 589M 634M 679M 673M
accountPayables 5M 7M 3M 7M 1M 3M 3M 2M 465 000
shortTermDebt 21M 21M 10M 10M 10M 10M 11M 12M 9M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 6M 3M 1M 49M 49M 20M 20M 20M 20M
otherCurrentLiabilities 12M 9M 17M -28M -25M -175 000 -1M 753 000 -365 000
totalCurrentLiabilities 43M 40M 31M 37M 35M 33M 34M 35M 29M
longTermDebt 61M 62M 63M 65M 67M 68M 69M 70M 71M
deferredRevenueNonCurrent 51M 51M 52M 49M 49M 20M 20M 20M 20M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 1M 1M 3M 3M 2M 3M 2M 3M 67M
totalNonCurrentLiabilities 113M 114M 118M 116M 117M 91M 91M 93M 96M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 71M 72M 63M 65M 77M 78M 80M 82M 80M
totalLiabilities 155M 155M 149M 153M 152M 124M 125M 128M 125M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 85 000 85 000 84 000 82 000 64 000 62 000 62 000 62 000 61 000
retainedEarnings -693M -643M -593M -544M -496M -450M -396M -344M -303M
accumulatedOtherComprehensiveIncomeLoss 1M -615 000 -500 000 272 000 -597 000 -754 000 -237 000 -694 000 -920 000
othertotalStockholdersEquity 1 200M 1 189M 1 177M 1 143M 957M 916M 906M 896M 852M
totalStockholdersEquity 509M 546M 583M 600M 460M 465M 509M 551M 548M
totalEquity 509M 546M 583M 600M 460M 465M 509M 551M 548M
totalLiabilitiesAndStockholdersEquity 664M 701M 732M 753M 612M 589M 634M 679M 673M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 664M 701M 732M 753M 612M 589M 634M 679M 673M
totalInvestments 381M 439M 467M 423M 407M 392M 425M 439M 274M
totalDebt 71M 72M 74M 75M 77M 78M 80M 82M 80M
netDebt -87M -69M -71M -131M -2M 8M -429M -33M -471M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VERV VERV VERV VERV VERV VERV VERV VERV VERV
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-05 2024-08-08 2024-05-08 2024-02-27 2023-11-07 2023-08-10 2023-05-15 2023-03-02 2022-11-07
acceptedDate 2024-11-05 07:30:23 2024-08-08 07:30:24 2024-05-08 07:30:33 2024-02-27 08:00:41 2023-11-07 07:30:31 2023-08-10 07:30:56 2023-05-15 07:33:51 2023-03-02 07:31:06 2022-11-07 07:33:07
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -50M -50M -49M -48M -46M -54M -52M -41M -45M
depreciationAndAmortization 2M 2M 2M 2M 1M 1M 1M 925 000 717 000
deferredIncomeTax 0 0 0 -11M -3M -4M 0 0 0
stockBasedCompensation 11M 12M 10M 9M 9M 9M 8M 7M 6M
changeInWorkingCapital -1M 6M -4M -2M 26M -3M -3M 3M 5M
accountsReceivables 410 000 3M 168 000 -3M 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables -3M 4M -3M 4M -2M -14 000 1M 1M -5M
otherWorkingCapital 1M -487 999 -904 000 -4M 28M -3M -1M 2M 10M
otherNonCashItems -924 000 5M 14M 10M 923 000 2M -3M -3M 4M
netCashProvidedByOperatingActivities -40M -34M -43M -41M -12M -48M -49M -33M -29M
investmentsInPropertyPlantAndEquipment -936 000 -980 000 -433 000 -2M -1M -3M -3M -5M -3M
acquisitionsNet 0 0 0 7M 11M -36M 0 0 0
purchasesOfInvestments -75M -112M -164M -122M -148M -113M -134M -257M -148M
salesMaturitiesOfInvestments 133M 143M 123M 116M 137M 149M 153M 94M 95M
otherInvestingActivites 0 31M -41M -7M -11M 36M 0 0 0
netCashUsedForInvestingActivites 57M 30M -42M -9M -12M 33M 15M -168M -56M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued -2M -51 000 23M 177M 32M -65 000 2M 39M 288M
commonStockRepurchased 472 000 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 14 000 1M -51 000 -393 000 148 000 1M 51 000 1M 503 000
netCashUsedProvidedByFinancingActivities 14 000 1M 23M 177M 32M 1M 2M 40M 288M
effectOfForexChangesOnCash 0 0 0 -15M -3M 18M 0 0 0
netChangeInCash 22M -3M -62M 128M 8M -14M -32M -162M 204M
cashAtEndOfPeriod 163M 141M 144M 206M 83M 75M 89M 120M 282M
cashAtBeginningOfPeriod 141M 144M 206M 78M 75M 89M 120M 282M 78M
operatingCashFlow -40M -34M -43M -41M -12M -48M -49M -33M -29M
capitalExpenditure -936 000 -980 000 -433 000 -2M -1M -3M -3M -5M -3M
freeCashFlow -41M -35M -44M -43M -13M -51M -52M -38M -32M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-11-05 12:00 ET
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
2024-11-01 20:26 ET
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-10-02 20:05 ET
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-09-03 20:05 ET
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-08-08 11:00 ET
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
2024-08-02 20:05 ET
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-07-01 20:05 ET
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-06-28 11:00 ET
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
2024-05-31 20:01 ET
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-05-31 11:00 ET
Verve Therapeutics Announces Leadership Update
2024-05-30 20:01 ET
Verve Therapeutics to Participate in Upcoming Investor Conferences
2024-05-08 11:00 ET
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
2024-05-07 11:00 ET
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
2024-05-03 20:01 ET
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-04-02 11:00 ET
Verve Therapeutics Announces Updates on its PCSK9 Program
2024-03-28 20:51 ET
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-03-01 21:01 ET
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 12:30 ET
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-01 11:30 ET
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2024-01-02 11:30 ET
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-01 21:00 ET
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
2023-11-29 03:37 ET
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
2023-11-28 21:01 ET
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
2023-11-12 20:30 ET
Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
2023-11-07 11:30 ET
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
2023-10-31 10:01 ET
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
2023-10-23 10:30 ET
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
2023-09-26 10:30 ET
Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
2023-09-21 20:05 ET
Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
2023-09-18 10:30 ET
Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
2023-08-10 10:30 ET
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
2023-08-03 10:30 ET
Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
2023-06-15 10:30 ET
Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease
2023-06-01 10:30 ET
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
2023-05-23 10:30 ET
Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day
2023-05-15 10:30 ET
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
2023-05-09 10:30 ET
Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference
2023-03-27 10:30 ET
Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
2023-03-03 11:30 ET
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
2023-03-02 11:30 ET
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-14 11:30 ET
Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
2023-01-03 21:05 ET
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-11-11 11:30 ET
Verve Therapeutics to Participate in Upcoming Investor Conferences
2022-11-07 11:30 ET
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
2022-10-31 11:00 ET
Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting
2022-09-22 10:30 ET
Verve Therapeutics to Participate in Upcoming Investor Conferences
2022-09-21 10:30 ET
Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
2022-08-22 10:30 ET
Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress
2022-08-09 10:30 ET
Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
2022-07-25 20:01 ET
Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2022-07-21 10:30 ET
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
2022-07-20 20:02 ET
Verve Therapeutics Announces Proposed Public Offering of Common Stock
2022-07-20 20:01 ET
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
2022-07-12 10:30 ET
Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia
2022-06-13 10:30 ET
Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors
2022-06-01 10:30 ET
Verve Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
2022-05-10 10:30 ET
Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
2022-05-09 10:30 ET
Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022
2022-05-04 10:30 ET
Verve Therapeutics to Participate in Upcoming May Investor Conferences
2022-04-26 10:30 ET
Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia
2022-04-04 10:30 ET
Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease
2022-03-24 10:30 ET
Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
2022-03-14 10:30 ET
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-23 11:30 ET
Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
2022-01-10 11:30 ET
Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs
2022-01-03 11:30 ET
Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-11-29 13:00 ET
Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer
2021-11-10 11:30 ET
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
2021-11-09 11:30 ET
Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates
2021-10-21 10:30 ET
Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit
2021-09-27 10:30 ET
Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
2021-08-12 10:30 ET
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results

SEC forms

Show financial reports only

SEC form 10
2025-05-14 11:30 ET
Verve Therapeutics, Inc. reported for 2025 q1
SEC form 8
2025-05-14 11:15 ET
Verve Therapeutics, Inc. reported for 2025 q1
SEC form 8
2025-05-14 11:15 ET
Verve Therapeutics, Inc. published news for 2025 q1
SEC form 10
2025-05-14 00:00 ET
Verve Therapeutics, Inc. reported for 2025 q1
SEC form 10
2025-02-27 00:00 ET
Verve Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Verve Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Verve Therapeutics, Inc. published news for 2024 q4
SEC form 10
2024-11-05 07:30 ET
Verve Therapeutics, Inc. reported for 2024 q3
SEC form 8
2024-11-05 07:15 ET
Verve Therapeutics, Inc. published news for 2024 q3
SEC form 8
2024-11-05 07:15 ET
Verve Therapeutics, Inc. reported for 2024 q3
SEC form 10
2024-08-08 07:30 ET
Verve Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-08 07:15 ET
Verve Therapeutics, Inc. published news for 2024 q2
SEC form 8
2024-08-08 07:15 ET
Verve Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Verve Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-08 07:30 ET
Verve Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-08 07:15 ET
Verve Therapeutics, Inc. published news for 2024 q1
SEC form 8
2024-05-08 07:15 ET
Verve Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-05-08 00:00 ET
Verve Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-02-27 08:00 ET
Verve Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Verve Therapeutics, Inc. published news for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q4
SEC form 10
2023-11-07 07:30 ET
Verve Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-07 07:00 ET
Verve Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-10 07:30 ET
Verve Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-10 07:00 ET
Verve Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-06-16 09:02 ET
Verve Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-15 06:37 ET
Verve Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-15 07:33 ET
Verve Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-15 07:00 ET
Verve Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-04-28 07:30 ET
Verve Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-03-02 07:31 ET
Verve Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-02 07:01 ET
Verve Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-02 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-02 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-02-17 06:31 ET
Verve Therapeutics, Inc. published news for 2022 q4
SEC form 6
2022-12-05 06:47 ET
Verve Therapeutics, Inc. published news for 2022 q3
SEC form 10
2022-11-07 07:33 ET
Verve Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-11-07 07:00 ET
Verve Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-11-02 16:25 ET
Verve Therapeutics, Inc. published news for 2022 q3
SEC form 10
2022-08-09 07:01 ET
Verve Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-08-09 06:45 ET
Verve Therapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-07-21 16:46 ET
Verve Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-07-21 07:01 ET
Verve Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-07-20 16:08 ET
Verve Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-07-12 07:00 ET
Verve Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-07-07 07:06 ET
Verve Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-06-13 16:34 ET
Verve Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-10 07:01 ET
Verve Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-10 06:48 ET
Verve Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Verve Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-29 07:01 ET
Verve Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-03-14 07:04 ET
Verve Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-14 06:49 ET
Verve Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-14 00:00 ET
Verve Therapeutics, Inc. published news for 2021 q4
SEC form 8
2022-03-14 00:00 ET
Verve Therapeutics, Inc. published news for 2021 q4
SEC form 6
2021-11-30 16:25 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-29 17:09 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 07:03 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-10 06:56 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-08-24 16:15 ET
Verve Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-16 08:01 ET
Verve Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-12 08:53 ET
Verve Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-12 08:20 ET
Verve Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-06-21 17:06 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:42 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:42 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:40 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:40 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:38 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:38 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:37 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:35 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:34 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:33 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:31 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:29 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:23 ET
Verve Therapeutics, Inc. published news for 2021 q1